NASDAQ: BTAI
Bioxcel Therapeutics Inc Stock Ownership - Who owns Bioxcel Therapeutics?

Insider buying vs selling

Have Bioxcel Therapeutics Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when BTAI insiders and whales buy or sell their stock.

BTAI Shareholders

What type of owners hold Bioxcel Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Vimal Mehta80.45%17,594,844$28.50MInsider
Bioxcel Holdings Inc80.33%17,566,750$28.46MInsider
Krishnan Nandabalan78.17%17,094,500$27.69MInsider
Vipin Agarwal39.12%8,554,945$13.86MInsider
Rashmi Agarwal39.12%8,554,945$13.86MInsider
Tarun K. Gupta39.10%8,550,396$13.85MInsider
Indu R. Gupta39.10%8,550,396$13.85MInsider
Suganthi Balasubramanian39.09%8,547,750$13.85MInsider
Diwakar Jain39.08%8,547,300$13.85MInsider
Anita Jain39.08%8,547,300$13.85MInsider

1 of 3

BTAI vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
BTAI1.18%98.82%
RADX0.01%0.00%
HOWL32.90%67.10%Net SellingNet Selling
RNXT19.45%11.62%Net BuyingNet Buying
CELU2.31%97.69%Net Selling

Bioxcel Therapeutics Stock Ownership FAQ

Who owns Bioxcel Therapeutics?

Bioxcel Therapeutics (NASDAQ: BTAI) is owned by 10.78% institutional shareholders, 905.17% Bioxcel Therapeutics insiders, and 0.00% retail investors. Vimal Mehta is the largest individual Bioxcel Therapeutics shareholder, owning 17.59M shares representing 80.45% of the company. Vimal Mehta's Bioxcel Therapeutics shares are currently valued at $28.50M.

If you're new to stock investing, here's how to buy Bioxcel Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.